Page last updated: 2024-12-05

trimesic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trimesic acid, also known as benzene-1,3,5-tricarboxylic acid, is a white solid organic compound with the formula C9H6O6. It is a symmetrical tricarboxylic acid, meaning it has three carboxyl groups (-COOH) attached to a benzene ring. The molecule is planar and has a 3-fold rotational symmetry. It is a relatively weak acid. Trimesic acid is a crystalline solid that is sparingly soluble in water. Trimesic acid can be synthesized by the oxidation of mesitylene with nitric acid. It is also produced by the hydrolysis of trimellitic anhydride. Trimesic acid is a useful building block in the synthesis of polymers, pharmaceuticals, and other organic compounds. Its rigid, planar structure makes it an excellent candidate for inclusion in porous organic cages. This area of research has grown rapidly, with trimesic acid being used as a building block in the formation of several metal-organic frameworks (MOFs). Trimesic acid is a highly interesting compound for the study of crystalline materials and has been investigated extensively in recent years. It exhibits a variety of interesting properties, including high thermal stability, high porosity, and excellent chemical resistance. These properties make it a promising candidate for use in a variety of applications, such as gas storage, catalysis, and separation. Research into trimesic acid is driven by its potential applications in various industries, including energy, pharmaceuticals, and materials science.'

trimesic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benzene-1,3,5-tricarboxylic acid : A tricarboxylic acid that consists of benzene substituted by carboxy groups at positions 1, 3 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11138
CHEMBL ID77562
CHEBI ID46032
SCHEMBL ID26189
MeSH IDM0190491

Synonyms (51)

Synonym
CHEMBL77562 ,
trimesitinic acid
nsc-3998
trimesinic acid
1,5-tricarboxybenzene
5-carboxyisophthalic acid
trimesic acid
nsc3998
554-95-0
inchi=1/c9h6o6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3h,(h,10,11)(h,12,13)(h,14,15
1,3,5-benzenetricarboxylic acid
benzene-1,3,5-tricarboxylic acid
trimesic acid, 95%
CHEBI:46032 ,
NCIOPEN2_009462
einecs 209-077-7
1,3,5-tricarboxybenzene
nsc 3998
ai3-06468
AC-907/25014230
B0043
bdbm50080275
DB08632
NCGC00248495-01
AKOS007930167
1,3,5-benzene tricarboxylic acid
dtxcid501488
dtxsid8021488 ,
cas-554-95-0
tox21_200017
NCGC00257571-01
A830674
ou36oo5mtn ,
unii-ou36oo5mtn
FT-0600423
SCHEMBL26189
AC-10237
W-105561
CS-0010336
mfcd00002517
h3btct
AC2199
trimesic acid, vetec(tm) reagent grade, 94%
SY007111
Q981152
STR04811
EN300-175524
benzene-1,3,5-tricarboxylicacid
BP-31127
Z1508914454
HY-78985

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" These compounds may serve as useful leads for the design of nonpeptide inhibitors of SH2 domains with improved bioavailability and metabolic stability compared to the natural ligands that contain phosphotyrosine."( NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain.
Fesik, SW; Hajduk, PJ; Zhou, MM, 1999
)
0.3
" The cytotoxicity and internalization assays conducted on 2D monolayers indicated that all CUR multicomponent solid forms except Curcumin-Folic Acid Dihydrate (CUR-FAD) (1:1) coamorphous solid exhibited enhanced bioavailability than unprocessed CUR."( New curcumin-trimesic acid cocrystal and anti-invasion activity of curcumin multicomponent solids against 3D tumor models.
Devidas Bhatia, D; Sathisaran, I; Vishvanath Dalvi, S, 2020
)
0.93
" Compared with commercial tablets, the relative bioavailability was 143."( Molecularly Imprinted Polymers Doped with Carbon Nanotube with Aid of Metal-Organic Gel for Drug Delivery Systems.
Chai, MH; Huang, YP; Liu, ZS; Yao, HF; Zhao, L, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" However, current treatments require frequent dosing that results in unstable plasma concentration and low bioavailability, risking serious adverse reactions."( Molecularly Imprinted Polymers Doped with Carbon Nanotube with Aid of Metal-Organic Gel for Drug Delivery Systems.
Chai, MH; Huang, YP; Liu, ZS; Yao, HF; Zhao, L, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tricarboxylic acidAn oxoacid containing three carboxy groups.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency69.49740.000714.592883.7951AID1259369
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.58700.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.56680.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein kinase LckHomo sapiens (human)Kd200.00000.00021.117424.2210AID99714
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID306538Induction of erythrocyte lysis at 100 uM2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Design of antimicrobial compounds based on peptide structures.
AID99714Binding affinity against Lck SH2 domain1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain.
AID306537Antibacterial activity against Bacillus subtilis2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Design of antimicrobial compounds based on peptide structures.
AID631930Dissociation constant, pKa of the compound2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID306536Antibacterial activity against Escherichia coli2007Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8
Design of antimicrobial compounds based on peptide structures.
AID631927Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (4.26)18.2507
2000's24 (25.53)29.6817
2010's54 (57.45)24.3611
2020's12 (12.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.32 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index82.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other96 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]